8-甲氧基-4,5-二氢-1H-苯并[d]氮杂革-2(3h)-酮 | 37682-06-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯氮卓类
• 中文名称: 8-甲氧基-4,5-二氢-1H-苯并[d]氮杂革-2(3h)-酮
• 中文别名: 8-甲氧基-4,5-二氢-1H-苯并[D]氮杂卓-2(3H)-酮
• 英文名称: 8-methoxy-1,3,4,5-tetrahydro-2H-benzo[d]azepin-2-one
• 英文别名: 8-methoxy-2,3,4,5-tetrahydro-2-oxo-1H-3-benzazepine；8-Methoxy-4,5-dihydro-1H-benzo[d]azepin-2(3H)-one；7-methoxy-1,2,3,5-tetrahydro-3-benzazepin-4-one
• CAS: 37682-06-7
• 化学式: C₁₁H₁₃NO₂
• mdl: MFCD11858006
• 分子量: 191.23
• InChiKey: WUNQZFYRIABBKP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.363
• 拓扑面积：
  38.3
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2933990090

反应信息

• 作为反应物：
  描述：

  8-甲氧基-4,5-二氢-1H-苯并[d]氮杂革-2(3h)-酮 在 硼烷四氢呋喃络合物 、 氢溴酸 、 四丁基碘化铵 、 sodium hydride 、 溶剂黄146 作用下， 以 四氢呋喃 、 二氯甲烷 、 溶剂黄146 、 二甲基亚砜 、 mineral oil 为溶剂， 反应 1.0h， 生成 6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-N-methyl-3-pyridinecarboxamide
  参考文献：
  名称：

  A new facile synthetic route to [11C]GSK189254, a selective PET radioligand for imaging of CNS histamine H3 receptor

  摘要：

  GSK189254 and its corresponding precursor GSK185071B were synthesized from 3-methoxyphenylacetic acid with 6-chloropyridine-3-carbolic acid or 6-chloronicotinamide in 8 and 7 steps with either 6% or 7% and either 14% or 16% yield, respectively. [C-11]GSK189254 was prepared from GSK185071B with [C-11]CH3OTf through N-[C-11] methylation and isolated by HPLC combined with solid-phase extraction (SPE) in 50-60% radiochemical yield based on [C-11]CO2 and decay corrected to end of bombardment (EOB), with 370-740 GBq/mu mol specific activity at EOB. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.05.076
• 作为产物：
  描述：

  3-甲氧基苯基乙酰氯 在 盐酸 、 palladium 10% on activated carbon 、 氢气 、 三甲胺 作用下， 以 二氯甲烷 、 水 、 溶剂黄146 为溶剂， 20.0 ℃ 、413.7 kPa 条件下， 反应 8.0h， 生成 8-甲氧基-4,5-二氢-1H-苯并[d]氮杂革-2(3h)-酮
  参考文献：
  名称：

  A new facile synthetic route to [11C]GSK189254, a selective PET radioligand for imaging of CNS histamine H3 receptor

  摘要：

  GSK189254 and its corresponding precursor GSK185071B were synthesized from 3-methoxyphenylacetic acid with 6-chloropyridine-3-carbolic acid or 6-chloronicotinamide in 8 and 7 steps with either 6% or 7% and either 14% or 16% yield, respectively. [C-11]GSK189254 was prepared from GSK185071B with [C-11]CH3OTf through N-[C-11] methylation and isolated by HPLC combined with solid-phase extraction (SPE) in 50-60% radiochemical yield based on [C-11]CO2 and decay corrected to end of bombardment (EOB), with 370-740 GBq/mu mol specific activity at EOB. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.05.076

文献信息

• BENZOAZEPIN-OXY-ACETIC ACID DERIVATIVES AS PPAR-DELTA AGONISTS USED FOR THE INCREASE OF HDL-C, LOWER LDL-C AND LOWER CHOLESTEROL
  申请人：Kuo Gee-Hong

  公开号：US20070244094A1

  公开（公告）日：2007-10-18

  The invention is directed to compounds of Formula (I) useful as PPAR agonists. Pharmaceutical compositions and methods of treating one or more conditions including, but not limited to, diabetes, nephropathy, neuropathy, retinopathy, polycystic ovary syndrome, hypertension, ischemia, stroke, irritable bowel disorder, inflammation, cataract, cardiovascular diseases, Metabolic X Syndrome, hyper-LDL-cholesterolemia, dyslipidemia (including hypertriglyceridemia, hypercholesterolemia, mixed hyperlipidemia, and hypo-HDL-cholesterolemia), atherosclerosis, obesity, and other disorders related to lipid metabolism and energy homeostasis complications thereof, using compounds of the invention are also described.

  该发明涉及一种化合物，其化学式为（I），可用作PPAR激动剂。还描述了使用该发明的化合物治疗糖尿病、肾病、神经病、视网膜病变、多囊卵巢综合征、高血压、缺血、中风、肠易激综合征、炎症、白内障、心血管疾病、代谢X综合征、高LDL胆固醇血症、血脂异常（包括高甘油三酯血症、高胆固醇血症、混合性高脂血症和低HDL胆固醇血症）、动脉粥样硬化、肥胖以及其他与脂质代谢和能量稳态并发症相关的疾病的药物组合物和治疗方法。
• Bronchorelaxing compounds
  申请人：Skogvall Staffan

  公开号：US20050165004A1

  公开（公告）日：2005-07-28

  A compound of the general formula (I) including its pharmaceutically acceptable acid addition salts wherein A is CHR 9 , wherein R 9 is H, C 1 -C 6 alkyl; n is 1-3; B is CHR 10 , wherein R 10 is H, C 1 -C 6 alkyl; m is 1 or 2; D is O or S or optionally NR 16 , wherein R 16 is H, C 1 -C 6 alkyl or C 2 -C 6 acyl; E is CR 11 R 12 or NR 13 , wherein R 11 and R 12 are, independent of each other, H or C 1 -C 6 alkyl, R 13 is H or C 1 -C 6 alkyl; F is C 1 -C 18 alkyl which may be mono- or di-unsaturated and/or substituted, is useful in treating and preventing pulmonary disease characterized by bronchoconstriction. Also disclosed are pharmaceutical compositions comprising the compound and methods for their manufacture.

  通用式（I）的化合物及其药学上可接受的酸盐包括其中 其中A为CHR 9 ，其中R 9 为H，C 1 -C 6 烷基；n为1-3；B为CHR 10 ，其中R 10 为H，C 1 -C 6 烷基；m为1或2；D为O或S或可选地为NR 16 ，其中R 16 为H，C 1 -C 6 烷基或C 2 -C 6 酰基；E为CR 11 R 12 或NR 13 ，其中R 11 和R 12 独立地为H或C 1 -C 6 烷基，R 13 为H或C 1 -C 6 烷基；F为C 1 -C 18 烷基，可以是单烯或双烯和/或取代的，用于治疗和预防以支气管痉挛为特征的肺部疾病。还公开了包含该化合物的药物组合物及其制备方法。
• Synthesis and evaluation of novel 2,4-diaminopyrimidines bearing bicyclic aminobenzazepines for anaplastic lymphoma kinase (ALK) inhibitor
  作者：Ga Ae Kang、Minji Lee、Dawn Song、Heung Kyoung Lee、Sunjoo Ahn、Chi Hoon Park、Chong Ock Lee、Chang Soo Yun、Heejung Jung、Pilho Kim、Jae Du Ha、Sung Yun Cho、Hyoung Rae Kim、Jong Yeon Hwang

  DOI：10.1016/j.bmcl.2015.07.004

  日期：2015.9

  A series of novel 2,4-diaminopyrimidine compounds bearing bicyclic aminobenzazepine were synthesized and evaluated for their anti-ALK activities. The activities of these compounds were confirmed in both enzyme- and cell-based ALK assays. Amongst compounds synthesized, KRCA-0445 showed very promising results in pharmacokinetic study and in vivo efficacy study with H3122 xenograft mouse model.

  合成了一系列带有双环氨基苯并ze庚因的新型2，4-二氨基嘧啶化合物，并评估了其抗ALK活性。这些化合物的活性均在基于酶和细胞的ALK分析中得到证实。在合成的化合物中，KRCA-0445在H3122异种移植小鼠模型的药代动力学研究和体内功效研究中显示出非常有希望的结果。
• [EN] TETRAHYDRO-BENZOAZEPINE GLYCOSIDASE INHIBITORS<br/>[FR] INHIBITEURS DE TÉTRAHYDRO-BENZOAZÉPINE GLYCOSIDASE
  申请人：ASCENEURON S A

  公开号：WO2020039028A1

  公开（公告）日：2020-02-27

  Compounds of formula (I') wherein A, R1, R2, T1, T2, T3, T4, L, W, Z, R''', m and n have the meaning according to the claims can be employed, inter alia, for the treatment of tauopathies and Alzheimer's disease.

  式(I')中A、R1、R2、T1、T2、T3、T4、L、W、Z、R'''、m和n的含义如权利要求书所述，可用于治疗tau病和阿尔茨海默病。
• Sulfinyl and sulfonyl substituted 2,3,4,5 tetrahydro-1H-3-benzazepines
  申请人：SmithKline Beckman Corporation

  公开号：US04824839A1

  公开（公告）日：1989-04-25

  Sulfinyl and sulfonyl substituted 3-benzazepine compounds are useful in treating gastrointestinal motility disorders and emesis. A particular compound of this invention is 7-methylsulfonyl-2,3,4,5-tetrahydro-1H-3-benzazepine.

  亚砜基和磺酰基取代的3-苯并噁啉化合物在治疗胃肠动力障碍和呕吐方面很有用。该发明的一种特定化合物是7-甲基磺酰基-2,3,4,5-四氢-1H-3-苯并噁啉。